Multidisciplinary Treatment of Prostate Cancer
Optimal treatment of prostate cancer requires a multidisciplinary team approach, with expertise needed in medical oncology, radiation oncology, urology, genetics, pathology, diagnostic radiology, and supportive care. It is important for clinicians who treat patients with prostate cancer to understand all facets of comprehensive care so that their patients receive the best possible treatments with effective management of side effects.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: Systemic Therapy Selection in Metastatic Castration-Resistant Prostate Cancer
The selection of systemic treatments in various lines of therapy for patients with metastatic castration-resistant prostate cancer (CRPC) has become more and more complicated over the last several years. Clinicians who work with patients with metastatic CRPC need to be educated on these updates so that they can help their patients make optimal treatment choices across lines of therapy.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
NCCN Pharmacy Updates: Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer
Relugolix has a unique place in therapy for the treatment of prostate cancer. As a first-in-class oral LHRH antagonist, relugolix provides many benefits for patients. However, it is critical to understand how to manage the potential toxicities, drug interactions and adherence issues when initiating and maintaining this new oral agent.
Category
  • Prostate Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date January 28, 2022